This review concluded that efficacy of low dose and standard dose antipsychotic medication may be comparable in preventing relapse in schizophrenia and schizoaffective disorders. Less than half the standard dose may increase the risk of overall treatment failure. The authors' conclusions reflect the evidence presented but the conclusions should be interpreted with caution because of a lack of details on quality assessment and the small number of included studies for each pooled outcome.
Authors' objectives
To compare the efficacy between standard dose versus low dose or very low dose of antipsychotics for relapse prevention in schizophrenia.
Searching
MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials (CENTRAL), Current Contents, E-Journals Database and Science Citation Index Expanded were searched up to August 2009. Search terms were reported. The were no language restrictions. Reference lists of relevant reviews and studies were screened. Pharmaceutical companies were contacted for any additional trials. ClinicalTrials.gov and the United States Food and Drug Administration website were searched for unpublished trials.
Study selection
Double-blind randomised controlled trials (RCTs) that compared standard dose versus low dose of antipsychotics for relapse prevention with a minimum follow-up duration of 24 weeks in patients with schizophrenia or schizoaffective disorder (defined using recognised criteria) were eligible for inclusion. Only trials of patients with stable psychopathology at baseline were included. Eligible trials had to involve a standard dose group with a mean dose ≥1 DDD (defined daily dose) unit and less than the upper limit of locally approved dose range. This was compared against either a very low dose group with a mean dose of <0.5 DDD unit or a low dose group with a mean dose of ≥0.5 and <1 DDD unit. The primary outcome was the rate of overall treatment failure (defined as discontinuation of assigned treatment for any reason). Secondary outcomes were the rate of hospitalisation, relapse and drop-outs due to side effects.
Most of the included studies evaluated first-generation antipsychotics; some studies evaluated second-generation antipsychotics. Definition of relapse varied between included studies. Study duration ranged between 24 and 104 weeks. The mean age of patients ranged from 28.3 to 50.1 years. Most studies included clinically stable ambulatory patients.
Two reviewers independently assessed studies for inclusion.
Assessment of study quality
The authors did not state that they assessed study quality.
Data extraction
Data were extracted on event rates to enable calculation of risk differences (RDs) with 95% confidence intervals (CIs) on an intention-to-treat basis. Study authors were contacted for missing data.
Two reviewers independently performed data extraction.
Methods of synthesis
The studies were combined in a meta-analysis. Pooled risk differences with 95% CIs were calculated with a randomeffects model. Where there were significant differences between treatment groups, the number needed to harm (NNH) 
